145757-50-2
Chemical Structure
N-Acetyl-L-leucyl-L-leucyl-L-methional
- CAS No.: 145757-50-2
- Formula:C18H33N3O4S
- Molecular Weight:387.54
IUPAC Name: 2-acetamido-4-methyl-N-(4-methyl-1-((4-(methylthio)-1-oxobutan-2-yl)amino)-1-oxopentan-2-yl)pentanamide
InChIKey: MALPUXYOAGJJGX-JYJNAYRXSA-N
SMILES: CC(C)C[C@@H](C(N)=O)N(C([C@H](CC(C)C)NC(C)=O)=O)[C@H](C=O)CCS
Biological Activity: N-Acetyl-L-leucyl-L-leucyl-L-methional is a Calpain II inhibitor with an IC50 of 0.24 μM against porcine Calpain II. N-Acetyl-L-leucyl-L-leucyl-L-methional forms a stable tetrahedral adduct with the thiol group at the active site of Calpain II, thereby inhibiting proteolytic activity. N-Acetyl-L-leucyl-L-leucyl-L-methionally inhibits cathepsins in a non-selective manner. N-Acetyl-L-leucyl-L-leucyl-L-methional reduces SARS-CoV-2 infection levels in human coronary artery endothelial cells in vitro. N-Acetyl-L-leucyl-L-leucyl-L-methional can be used in research related to cataracts and coronavirus infections[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
N-Acetyl-L-leucyl-L-leucyl-L-methional | N-Acetyl-L-leucyl-L-leucyl-L-methional is a Calpain II inhibitor with an IC50 of 0.24 μM against porcine Calpain II. N-Acetyl-L-leucyl-L-leucyl-L-methional forms a stable tetrahedral adduct with the thiol group at the active site of Calpain II, thereby inhibiting proteolytic activity. N-Acetyl-L-leucyl-L-leucyl-L-methionally inhibits cathepsins in a non-selective manner. N-Acetyl-L-leucyl-L-leucyl-L-methional reduces SARS-CoV-2 infection levels in human coronary artery endothelial cells in vitro. N-Acetyl-L-leucyl-L-leucyl-L-methional can be used in research related to cataracts and coronavirus infections. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Lampi KJ, et al. Comparison of Cell-Permeable Calpain Inhibitors and E64 in Reduction of Cataract in Cultured Rat Lenses. Toxicol Appl Pharmacol. 1992;117:53-57. [Content Brief]
- [2]. Lang PA, et al. PGE(2) in the regulation of programmed erythrocyte death. Cell death and differentiation. 2005 May;12(5):415-28. [Content Brief]
- [3]. Wagner JUG, et al. Increased susceptibility of human endothelial cells to infections by SARS-CoV-2 variants. Basic research in cardiology. 2021 Jul 05;116(1):42. [Content Brief]
